TY  - JOUR
AU  - Lundstrom, Kenneth
AU  - Hromić-Jahjefendić, Altijana
AU  - Bilajac, Esma
AU  - Aljabali, Alaa
AU  - Baralić, Katarina
AU  - Sabri, Nagwa
AU  - Shehata, Eslam
AU  - Raslan, Mohamed
AU  - Raslan, Sara
AU  - Ferreira, Ana Cl ́audia
AU  - Orlandi, Lidiane
AU  - Serrano-Aroca, Angel
AU  - Uversky, Vladimir
AU  - Hassan, Sk. Sarif
AU  - Redwan, Elrashdy
AU  - Azevedo, Vasco
AU  - Alzahrani, Khalid
AU  - Alsharif, Khalaf
AU  - Halawani, Ibrahim
AU  - Alzahrani, Fuad
AU  - Tambuwala, Murtaza
AU  - Barh, Debmalya
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4365
AB  - The COVID-19 pandemic has triggered intensive research and development of drugs and vaccines against SARS-CoV-2 during the last two years. The major success was especially observed with development of vaccines based on viral vectors, nucleic acids and whole viral particles, which have received emergent authorization leading to global mass vaccinations. Although the vaccine programs have made a big impact on COVID-19 spread and severity, emerging novel variants have raised serious concerns about vaccine efficacy. Due to the urgent demand, drug development had originally to rely on repurposing of antiviral drugs developed against other infectious diseases. For both drug and vaccine development the focus has been mainly on SARS-CoV-2 surface proteins and host cell receptors involved in viral attachment and entry. In this review, we expand the spectrum of SARS-CoV-2 targets by investigating the COVID-19 signalome. In addition to the SARS-CoV-2 Spike protein, the envelope, membrane, and nucleoprotein targets have been subjected to research. Moreover, viral proteases have presented the possibility to develop different strategies for the inhibition of SARS-CoV-2 replication and spread. Several signaling pathways involving the renin-angiotensin system, angiotensin-converting enzymes, immune pathways, hypoxia, and calcium signaling have provided attractive alternative targets for more efficient drug development.
PB  - Elsevier Inc.
T2  - Cellular Signalling
T1  - COVID-19 signalome: Potential therapeutic interventions
VL  - 103
DO  - 10.1016/j.cellsig.2022.110559
ER  - 

@article{
author = "Lundstrom, Kenneth and Hromić-Jahjefendić, Altijana and Bilajac, Esma and Aljabali, Alaa and Baralić, Katarina and Sabri, Nagwa and Shehata, Eslam and Raslan, Mohamed and Raslan, Sara and Ferreira, Ana Cl ́audia and Orlandi, Lidiane and Serrano-Aroca, Angel and Uversky, Vladimir and Hassan, Sk. Sarif and Redwan, Elrashdy and Azevedo, Vasco and Alzahrani, Khalid and Alsharif, Khalaf and Halawani, Ibrahim and Alzahrani, Fuad and Tambuwala, Murtaza and Barh, Debmalya",
year = "2023",
abstract = "The COVID-19 pandemic has triggered intensive research and development of drugs and vaccines against SARS-CoV-2 during the last two years. The major success was especially observed with development of vaccines based on viral vectors, nucleic acids and whole viral particles, which have received emergent authorization leading to global mass vaccinations. Although the vaccine programs have made a big impact on COVID-19 spread and severity, emerging novel variants have raised serious concerns about vaccine efficacy. Due to the urgent demand, drug development had originally to rely on repurposing of antiviral drugs developed against other infectious diseases. For both drug and vaccine development the focus has been mainly on SARS-CoV-2 surface proteins and host cell receptors involved in viral attachment and entry. In this review, we expand the spectrum of SARS-CoV-2 targets by investigating the COVID-19 signalome. In addition to the SARS-CoV-2 Spike protein, the envelope, membrane, and nucleoprotein targets have been subjected to research. Moreover, viral proteases have presented the possibility to develop different strategies for the inhibition of SARS-CoV-2 replication and spread. Several signaling pathways involving the renin-angiotensin system, angiotensin-converting enzymes, immune pathways, hypoxia, and calcium signaling have provided attractive alternative targets for more efficient drug development.",
publisher = "Elsevier Inc.",
journal = "Cellular Signalling",
title = "COVID-19 signalome: Potential therapeutic interventions",
volume = "103",
doi = "10.1016/j.cellsig.2022.110559"
}

Lundstrom, K., Hromić-Jahjefendić, A., Bilajac, E., Aljabali, A., Baralić, K., Sabri, N., Shehata, E., Raslan, M., Raslan, S., Ferreira, A. C. ́., Orlandi, L., Serrano-Aroca, A., Uversky, V., Hassan, Sk. S., Redwan, E., Azevedo, V., Alzahrani, K., Alsharif, K., Halawani, I., Alzahrani, F., Tambuwala, M.,& Barh, D.. (2023). COVID-19 signalome: Potential therapeutic interventions. in Cellular Signalling
Elsevier Inc.., 103.
https://doi.org/10.1016/j.cellsig.2022.110559

Lundstrom K, Hromić-Jahjefendić A, Bilajac E, Aljabali A, Baralić K, Sabri N, Shehata E, Raslan M, Raslan S, Ferreira AĆ, Orlandi L, Serrano-Aroca A, Uversky V, Hassan SS, Redwan E, Azevedo V, Alzahrani K, Alsharif K, Halawani I, Alzahrani F, Tambuwala M, Barh D. COVID-19 signalome: Potential therapeutic interventions. in Cellular Signalling. 2023;103.
doi:10.1016/j.cellsig.2022.110559 .

Lundstrom, Kenneth, Hromić-Jahjefendić, Altijana, Bilajac, Esma, Aljabali, Alaa, Baralić, Katarina, Sabri, Nagwa, Shehata, Eslam, Raslan, Mohamed, Raslan, Sara, Ferreira, Ana Cl ́audia, Orlandi, Lidiane, Serrano-Aroca, Angel, Uversky, Vladimir, Hassan, Sk. Sarif, Redwan, Elrashdy, Azevedo, Vasco, Alzahrani, Khalid, Alsharif, Khalaf, Halawani, Ibrahim, Alzahrani, Fuad, Tambuwala, Murtaza, Barh, Debmalya, "COVID-19 signalome: Potential therapeutic interventions" in Cellular Signalling, 103 (2023),
https://doi.org/10.1016/j.cellsig.2022.110559 . .